• Cognitive Remediation in ADHD Children : Comparison Between Three Therapeutic Strategies : Cognitive Remediation With a Virtual Classroom Software and Methylphenidate and Supportive Psychotherapy

  NCT01821170

  CompletedInterventionalNot ApplicableUpdated May 14, 2026
• Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder

  NCT02210728

  Unknown statusInterventionalNot ApplicableUpdated Aug 28, 2018
• Feasibility and Efficacy of Cognitive-Behavioral Therapy for Patients With ADHD/Behavioral Addiction Comorbidity

  NCT06797726

  RecruitingInterventionalNot ApplicableUpdated Jun 25, 2025
• Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

  NCT00015223

  CompletedInterventionalPhase 2Updated Jan 16, 2017
• Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With ADHD

  NCT03411434

  Unknown statusInterventionalNot ApplicableUpdated Jan 26, 2018
• Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

  NCT04178993

  CompletedInterventionalPhase 1Updated Jan 9, 2023

ClinicalTrials.gov ID

NCT06906328

Lead Sponsor

Nantes University HospitalOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

248Estimated

Last Update Posted

Feb 19, 2026Actual

Start Date

Dec 11, 2025Actual

Primary Completion Date

Dec 11, 2028Estimated

Completion Date

Dec 11, 2029Estimated

Official Title

MEthylphenidate in ADHD - Addiction(s) Comorbidity: Value of Adding a Cognitive Remediation Program to Improve Short- and Medium-term Therapeutic Response

Brief Summary

MEthylphenidate in ADHD - Addiction(s) comorbidity: benefit of adding a cognitive remediation program to improve short- and medium-term therapeutic response

Detailed Description

It seems essential to optimize the therapeutic management of patients suffering from ADHD/addiction(s) comorbidity by specifically targeting their neuropsychological deficits, in addition to the pharmacological and psychosocial approaches currently recommended. By intensively training deficient functions on the one hand, and promoting the development of compensatory strategies on the other, cognitive remediation could thus be a therapeutic tool of choice, producing beneficial effects that persist over time and translate into objectifiable changes in daily life. Cognitive training programs have been successfully proposed to patients with ADHD, but these were mainly programs designed for children, and very few studies have been carried out in adults, a fortiori in adults with ADHD-addiction(s) comorbidity.

The main aim of the study was to evaluate the effectiveness of cognitive remediation compared with the control program in addition to MPH treatment in reducing the functional impact of ADHD in patients with other addictive comorbidities, at the end of treatment.

• ADHD-add

• Cognitive remediation program, with the PRESCO® software
• Control program, with the AUDITICO® software

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age over 18;
• Diagnosis of ADHD confirmed by DIVA-5 interview following a specialized ADHD-addiction(s) consultation;
• Indication for MPH treatment according to European recommendations (J. J. S. Kooij et al., 2019) and absence of contraindications (particularly cardiological);
• Presence of at least one comorbid addictive disorder (SUD and/or BA);
• Having given their consent to take part in the study;
• Being affiliated to the French social security system or benefiting from such a system.

Exclusion Criteria:

• Presence of disorders of the higher functions or difficulties in reading or writing the French language making it impossible to collect data;
• Pregnant or breast-feeding woman;
• Person deprived of liberty;
• Person under compulsory psychiatric care;
• Participation in another interventional research protocol involving another psychotherapeutic or pharmacological intervention that may have an impact on clinical outcome;
• Guardianship or safeguard of justice.
• Patients who consumned psychoactive substances within 12 hours prior to their visit.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

Nantes University HospitalOTHER

clemence.cabelguen@chu-nantes.fr02 40 84 61 16